sur BIOMERIEUX (EPA:BIM)
BioMérieux Acquires Day Zero Diagnostics to Enhance Sequencing Abilities
On June 16, 2025, bioMérieux announced a strategic acquisition of Day Zero Diagnostics, a US-based company specializing in infectious disease diagnostics. This move aims to advance bioMérieux's next-generation sequencing (NGS) capabilities. The acquisition supports the company's commitment to healthcare advancement and antimicrobial stewardship.
Day Zero Diagnostics has pioneered technologies that enable rapid bacterial pathogen identification and antibiotic resistance profiling directly from whole blood samples, significantly reducing diagnostics time from days to hours. This includes NGS workflows and bioinformatics software now part of bioMérieux's assets.
The integration of these solutions enhances bioMérieux's R&D pipeline to meet critical needs in infectious disease diagnostics, such as the management of severe conditions like sepsis. This acquisition, valued at under USD 25 million, bolsters bioMérieux's long-term growth strategy beyond 2028.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de BIOMERIEUX